Skip to Main Content
Contribute Try STAT+ Today

Waltham-based Adagio Therapeutics announced on Monday that it has raised $336 million in new funding to rapidly advance its Covid-19 antibody treatment, which aims to treat and prevent the disease and all of its known variants.

Last week the Waltham biotech began recruitment for global clinical trial to test the drug’s efficacy as a treatment for high-risk individuals with mild or moderate Covid-19. The goal: to determine whether a single intramuscular dose could prevent hospitalizations and deaths.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Comments are closed.